Fast Track

Growth in Rare Disease Impacts Drug Development and Strategy

Jul 10, 2019 | Drug Development, Fast Track, Orphan Drug, PDUFA, Rare Diseases

About 33% of all drugs in active R&D pipelines are now included in the rare disease category. This categorization presents scientific and operational challenges to sponsors and clinical trial ecosystem participants, the adoption of new strategies, operating models...

TRIALSITE NEWS IS THE ONLY DIGITAL MEDIA DEDICATED 100% TO TRANSPARENT AND OPEN COVERAGE OF CLINICAL RESEARCH TRIAL SITES AROUND THE GLOBE. BASED IN THE SILICON SLOPES IN DOWNTOWN SALT LAKE CITY, UTAH, WE ARE FOUNDED BY A TEAM OF EXPERTS IN THE CLINICAL TRIALS INDUSTRY AND DEDICATED TO TRANSPARENCY, QUALITY AND CLINICAL TRIAL INNOVATION.

159 WEST BROADWAY SUITE 200
SALT LAKE CITY, UT 84101

Growth in Rare Disease Impacts Drug Development and Strategy

Pin It on Pinterest